Clinical trials: Cytarabine, completed
Leukemia, Acute Myeloid Leukemia
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
The goal of this clinical research study is to find out if standard chemotherapy given with idarubicin and Cytarabine (ara-C) can help to control AML.
- Conditions
- Leukemia, Acute Myeloid Leukemia, AML
- Trial name
- NCT00422591
- Testing
- Cytarabine, Idarubicin
- Where
- United States
- Volunteers
- 175 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma
The purpose of this study is to find out what effects (good and/or bad) treatment with chemotherapy and stem cell transplant compared with chemotherapy alone will have on primary CNS B-cell lymphoma.
- Trial name
- NCT01511562
- Testing
- carmustine, cytarabine, etoposide
- Where
- 126 sites in United States
- Volunteers
- 113 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphoma
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00020943
- Testing
- filgrastim, rituximab, carmustine
- Where
- 81 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Acute Myeloid Leukemia
Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML
This protocol corresponds to a multicenter, open-label, non-randomized, phase I study designed to determine the safety of the combination of selinexor with chemotherapy in young patients with relapsed or refractory AML.
- Trial name
- FLAGINEXOR (NCT03661515)
- Testing
- Selinexor, fludarabine, idarubicin
- Where
- 4 sites in Spain
- Volunteers
- 16 people
- Sponsor
- PETHEMA Foundation
Acute Myeloid Leukemia
Timed-Sequential Induction in CBF-AML
Core binding factor (CBF) acute myeloid leukemias (AML) include AMLs carrying the t(8;21) translocation as well as AMLs carrying either the inversion of chromosome 16 or translocation t(16;16).
- Trial name
- NCT00428558
- Testing
- Chemotherapy (DAUNORUBICINE-CYTARABINE)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Lymphoma
Rituximab Combined With ESHAP in Patients With Relapse or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
The purpose of this study is to evaluate the efficacy and toxicity of Rituximab combined with ESHAP (etoposide, methylprednisolone, cytarabine, and cisplatin) in the patients with diffuse large B cell lymphoma (DLBCL).
- Trial name
- NCT00568815
- Testing
- Rituximab combined with ESHAP
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Fudan University
Acute,Leukemia, Lymphoid
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
In this single-center, open-label, no control,prospective clinical trial, a total of 30 Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) patients will be enrolled.
- Trial name
- NCT02523976
- Testing
- Dasatinib, prednisone, cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Adult Acute Lymphocytic Leukemia
Trial for Treatment of Adult Patients With Standard Risk Acute Lymphoblastic Leukemia With Chemotherapy and Rituximab
The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy in combination with rituximab in CD20 positive standard risk patients.
- Trial name
- NCT00199004
- Testing
- Cyclophosphamide, Dexamethasone / Prednisolone, Vincristine
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Relapsed/Refractory Acute Myeloid Leukemia
A Randomized Trial of a Combination of Nintedanib/Placebo in Combination With Induction Chemotherapy for Patients With Refractory or First Relapse Acute Myeloid Leukemia
The purpose of this study is to determine if a combination of nintedanib+ induction chemotherapy can be an effective strategy for patients where outcome of relapse/refractory acute myeloid leukemia (AML) is poor.
- Trial name
- NCT02665143
- Testing
- Nintedanib and AML induction
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Yale University
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia
Phase I trial to study the effectiveness of combining oblimersen with cytarabine and daunorubicin in treating older patients who have previously untreated acute myeloid leukemia.
- Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Trial name
- NCT00039117
- Testing
- oblimersen sodium, cytarabine, daunorubicin hydrochloride
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib
The long-term outcome of patients with acute myeloid leukemia (AML) remains poor, with less than 30% of patients achieving long lasting remission or cure.
- Trial name
- TEAM (NCT04173585)
- Testing
- Bortezomib, Gemtuzumab Ozogamicin
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital Heidelberg
Myelodysplastic Syndrome
Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML
The purpose of this study is to find out the effectiveness and side effects of arsenic trioxide in combination with low-dose ara-C.
- Trial name
- NCT00195104
- Testing
- Arsenic Trioxide (Tricenox), Cytarabine
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Weill Medical College of Cornell University
Lymphoma
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Trial name
- NCT00007852
- Testing
- rituximab, carmustine, cytarabine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Nebraska
Hodgkin Lymphoma
Combination of Nivolumab and DHAP in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (Nivo-DHAP)
A clinical study of safety and efficacy of treatment with Nivolumab and DHAP in patients with relapsed/refractory Hodgkin's lymphoma
- Trial name
- Nivo-DHAP (NCT04091490)
- Testing
- Nivolumab
- Where
- Russia
- Volunteers
- 40 people
- Sponsor
- State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Leukemia
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
RATIONALE: Giving chemotherapy before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT00070174
- Testing
- asparaginase, busulfan, cyclophosphamide
- Where
- 148 sites in United States, Australia and 3 more
- Volunteers
- 350 people
- Sponsor
- Children's Oncology Group